Free Trial

Cytokinetics Q3 2023 Earnings Report

Cytokinetics logo
$48.87 +2.13 (+4.56%)
(As of 12/20/2024 05:31 PM ET)

Cytokinetics EPS Results

Actual EPS
-$1.35
Consensus EPS
-$0.72
Beat/Miss
Missed by -$0.63
One Year Ago EPS
N/A

Cytokinetics Revenue Results

Actual Revenue
$0.38 million
Expected Revenue
$24.71 million
Beat/Miss
Missed by -$24.33 million
YoY Revenue Growth
N/A

Cytokinetics Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Is Starlink Set For The Largest IPO In History? (Ad)

He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000!

Click here now for the urgent details.

Cytokinetics Earnings Headlines

Why Cytokinetics Stock Was a Nearly 5% Winner Today
Is Starlink Set For The Largest IPO In History?
He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000!
Cytokinetics price target raised to $82 from $80 at RBC Capital
See More Cytokinetics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cytokinetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cytokinetics and other key companies, straight to your email.

About Cytokinetics

Cytokinetics (NASDAQ:CYTK), a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

View Cytokinetics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings